To cover the experience of PH patients since the start of the pandemic in different countries, a survey was jointly initiated by the ERS Assembly 13 on Pulmonary Vascular Diseases, ERS Clinical Research Collaboration PHAROS, European Reference Network for rare lung diseases (ERN-Lung), and endorsed by patient association PHA Europe. The survey aimed to collect data on the clinical course and treatment of COVID positive PH patients (concerns only group 1 and 4, PAH and CTEPH) and data on hospitalisations, ICU admissions and outcomes.
The results from this survey are now out – you may view them here. Thank you for participating in the survey. Your feedback is invaluable and will be used as the basis to give evidence-based guidance to our patients in the future.